Seneca Therapeutics Website, Blog & Press Pages

Seneca Therapeutics Website, Blog & Press Pages - aVenture

Seneca Therapeutics - Library

1 page

Platform/platform
Seneca’s lead asset, SVV-001, is an oncolytic virus that selectively replicates in and kills certain tumor cells expressing TEM8.

1 page

Elevated expression of ANTXR1 gene in tumors is a poor prognostic biomarker for patients with bladder cancer/news/elevated-expression-of-antxr1-gene-in-tumors-is-a-poor-prognostic-biomarker-for-patients-with-bladder-cancer
The TEM8 protein coded by the ANTXR1 gene represents an emerging biomarker in solid tumors. In addition to the various roles TEM8 plays in oncogenesis, including angiogenesis, epithelial-to-mesenchymal transition, and cell migration, it has also been shown that the overexpression of the ANTXR1 g

5 pages

Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at World Vaccine Congress/news/dr-paul-hallenbeck-cso-and-president-of-seneca-therapeutics-to-present-at-world-vaccine-congress
Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at World Vaccine Congress November 28, 2023
News/news
Funding Provides 2+ Years Runway to Complete Phase I/II Trial of Seneca Vally Virus (SVV-001) Currently Underway in High-Grade Neuroendocrine Neoplasms
Seneca Therapeutics Announces Publication of TEM8 Review Article “TEM8 in Oncogenesis” in Cells Journal/news/seneca-therapeutics-announces-publication-of-tem8-review-article-tem8-in-oncogenesis-in-cells-journal
November 15, 2023 06:00 AM Eastern Standard Time PHILADELPHIA--( BUSINESS WIRE )--Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells. The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett
Seneca Therapeutics Announces the Closing of $3.9 million Series B Extension Round/news/seneca-therapeutics-announces-the-closing-of-39-million-series-b-extension-round
Funding Provides 2+ Years Runway to Complete Phase I/II Trial of Seneca Vally Virus (SVV-001) Currently Underway in High-Grade Neuroendocrine Neoplasms Read more

1 page

Our Team/our-team
Mr. Smart is CEO of Seneca Therapeutics. He previously led Actym Therapeutics, Gravitas Therapeutics, and AnaptysBio as CEO, and held roles at XOMA, Genetics Institute, GenVec, and Searle.

1 page

1 page